On Wednesday, July 29, Conmed CNMD will report its last quarter's earnings. Here is Benzinga's preview of the company's release.
Earnings and Revenue
Wall Street analysts see Conmed reporting a loss of $0.98 per share on revenue of $124.92 million. Conmed earnings in the same period a year ago was $0.560 per share. Quarterly sales came in at $238.26 million. The analyst consensus estimate would represent a 275.0% decrease in the company's earnings. Revenue would be down 43.66% from the same quarter last year. Here's how the company's EPS has stacked up against analyst estimates in the past:
| Quarter | Q1 2020 | Q4 2020 | Q3 2019 | Q2 2019 |
|---|---|---|---|---|
| EPS Estimate | 0.54 | 0.89 | 0.56 | 0.53 |
| EPS Actual | 0.51 | 0.90 | 0.62 | 0.56 |
| Revenue Estimate | 221.71 M | 265.57 M | 227.93 M | 233.26 M |
| Revenue Actual | 214.01 M | 264.87 M | 233.59 M | 238.26 M |
Stock Performance
Shares of Conmed were trading at $84.65 as of July 28. Over the last 52-week period, shares are down 3.96%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.
Considering these returns, shareholders will likely be feeling unsatisfied going into this earnings release.
Don't be surprised to see the stock move on comments made during its conference call. Conmed is scheduled to hold the call at 16:30:00 ET and can be accessed here: https://edge.media-server.com/mmc/p/dannmu9s
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
